An interventional study of Growth Hormone and Pegisomant in Metabolic Diseases and Growth Hormone Treatment, sponsored by University of Aarhus. Completed at 1 site in Denmark. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-26.
Sponsored by University of Aarhus · Not applicable, Interventional, and Basic science
Growth hormone (GH) induces fat metabolism. The mechanisms underlying the fat metabolizing effects of GH remain elusive. However, it is known that insulin suppresses fat metabolism, and GH inhibits the expression of certain insulin-dependent signaling proteins. We therefore hypothesize that the fat metabolizing effects of GH depend on abrogation of insulin-dependent signaling pathways.
In order to investigate the fat metabolizing effects of GH, we'll analyze consecutive adipose tissue biopsies taken after GH exposure and GH blocking, respectively.
Knowledge of the effects of growth hormone and fat metabolism can in shot-sight as well as in long-sight have great importance for the understanding of growth disorders from overweight and type 2 diabetes to malnutrition and eating disorders.
997 studies on the registry are indexed under Metabolic Diseases; 234 are open to participants now.
This study's enrollment of 9 is below the median of 48 across 670 interventional studies indexed under Metabolic Diseases.
Browse Metabolic Diseases studies →University of Aarhus is the lead sponsor of 1,274 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Subjects are receiving growth hormone
Drug: Growth Hormone
Subjects are receiving pegvisomant to block the action of growth hormone
Drug: Pegisomant
Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg
Also known as: Genotropin
One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone
Also known as: Somavert
Lipolytic activity measured as area under the curve (AUC) for FFA (blood sample).
Time frame: 1 year
Substrate metabolism as measured by indirect calorimetry
Time frame: 3 months
GH signaling proteins in adipose tissue measured by western blotting
Time frame: 1,5 years
Intracellular lipolytic activity measured by an ATGL assay
Time frame: 1 year
GH signaling gene targets in adipose tissue measured by qPCR
Time frame: 1,5 years
Plan to share: No
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Aarhus